ALNY - Alnylam initiates mid-stage zilebesiran hypertension study

Alnylam Pharmaceuticals (NASDAQ:ALNY) announces the initiation of a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), which is being developed as a treatment for hypertension. The trial will evaluate the efficacy and safety of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by standard of care antihypertensive medications. The primary endpoint is the change from baseline in 24-hour mean systolic blood pressure (SBP) after three months of treatment, as measured by ambulatory blood pressure monitoring (ABPM). Additional endpoints will include change from baseline in blood pressure at six months and time-averaged reduction of blood pressure as a measure of tonic control.

For further details see:

Alnylam initiates mid-stage zilebesiran hypertension study